Sano, Myriad Genetics withdraw proposed public offerings due to market weakness.
SANO HABITROL GENERIC COULD BE MARKETED BY PAR, if FDA approves the company's ANDA for a version of Ciba's nicotine transdermal patch for smoking cessation, according to a recent prospectus for a proposed public offering. Sano filed its ANDA in January 1995 and has "received comments from the FDA...and has responded to those comments," the prospectus states. Sano's manufacturing facilities passed an FDA preapproval inspection in July 1996.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth